- Source : Press Release
- Date : 2019-02-11
- Companies : Elanix Biotechnologies SA
Elanix Biotechnologies AG Annuls Profit Guidance and Preliminary Earnings for FY 2017
Berlin, 11 February 2019 - In the management report for the 2016 financial year, Elanix Biotechnologies AG ("Company") had amongst others reported that sales revenues of between EUR 300,000 and EUR 500,000 are expected in the 2017 financial year. Accordingly, revenues in the amount of EUR 328,148 were reported in the preliminary consolidated financial statements for FY 2017. Both reports have been prepared and signed during the tenure of former CEO Tomas J. Svoboda
Additionally, other mis-management has been detected concerning outstanding loans (associated with specific conditions along with various payments without contracts) which are still under scrutiny.
Lee Ann Laurent-Applegate
Elanix Biotechnologies AG
Elanix develops and commercializes tissue regeneration products for acute wound care, dermatological and gynecological applications, and provides services in cell technologies. The company was founded in 2012 as a spin-out from the University Hospital of Lausanne (CHUV), Switzerland, to commercialize a patented human progenitor cell technology. Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing.
11-Feb-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Company:||Elanix Biotechnologies AG|
|Phone:||41 22 363 66 40|
|Fax:||41 22 363 66 41|
|Listed:||Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf